Biocon’s arm inks pact with Amgen to commercialize Denosumab biosimilars in Europe, ROW

02 Dec 2025 Evaluate

Biocon’s subsidiary -- Biocon Biologics has entered into settlement agreement with Amgen Inc. that clears the path for the commercialization of its Denosumab biosimilars in Europe and the rest of the world (ROW). The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025. The other terms of the settlement remain confidential.

The European Commission (EC) had approved Vevzuo and Evfraxy in July 2025. Biocon Biologics had secured a market entry date for its Denosumab biosimilars Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) for the United States previously.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

377.80 2.55 (0.68%)
13-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1698.10
Dr. Reddys Lab 1267.60
Cipla 1330.85
Zydus Lifesciences 904.85
Lupin 2199.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×